{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:37:35Z","timestamp":1757309855494,"version":"3.41.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"ANID-CONICYT FONDECYT","award":["1212006, 1190419 and 11251675"],"award-info":[{"award-number":["1212006, 1190419 and 11251675"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Primary aldosteronism (PA) is the main cause of secondary arterial hypertension. In this study, we present the medical treatment of Hispanic patients with PA followed for up to 5 years, highlighting the complete cure with pharmacological treatment in one of our patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We studied 32 PA patients, followed every 6 months after starting MRA. A clinical response was the normalization of blood pressure (BP) in the absence of other antihypertensive drugs. The biochemical response was considered with normalization of potassium and renin. Responses to treatment were compared using the defined daily dose (DDD). The effect of MRA was evaluated in vitro. The HAC15 cells were cultured and stimulated with aldosterone and spironolactone for 24\u201372 h, and the apoptotic cell death was measured.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>At 12 months posttreatment with MRA, 68% of the patients had a total clinical response, and 67% had a total biochemical response. Response to MRA treatment reduced DDD by an average of 74%. Additionally, we observed one PA patient treated with spironolactone after 3 years, he presented a pharmacological cure with normalization of aldosterone and renin without treatment with spironolactone. The in vitro study shows that spironolactone increased early apoptosis by 60% and late apoptosis by 50%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>These results suggest the importance of timely diagnosis of PA and specific treatment with MRA, especially in patients with a poor response to treatment. Moreover, remission of PA may occur in some patients after spironolactone treatment due to its suggestive role as an apoptotic agent.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpaf020","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T11:27:51Z","timestamp":1739878071000},"page":"354-360","source":"Crossref","is-referenced-by-count":1,"title":["Primary Aldosteronism in a Hispanic Cohort: Responses to Mineralocorticoid Receptor Antagonism and Remission in a Case"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-1468","authenticated-orcid":false,"given":"Alejandra","family":"Tapia-Castillo","sequence":"first","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago ,","place":["Chile"]},{"name":"Centro Traslacional de Endocrinolog\u00eda UC (CETREN-UC) , Santiago ,","place":["Chile"]},{"name":"Faculty of Engineering, Universidad Finis Terrae , Santiago ,","place":["Chile"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Vecchiola","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago ,","place":["Chile"]},{"name":"Centro Traslacional de Endocrinolog\u00eda UC (CETREN-UC) , Santiago ,","place":["Chile"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Qui\u00f1ones","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago ,","place":["Chile"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Baudrand","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago ,","place":["Chile"]},{"name":"Centro Traslacional de Endocrinolog\u00eda UC (CETREN-UC) , Santiago ,","place":["Chile"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-855X","authenticated-orcid":false,"given":"Thomas","family":"Uslar","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago ,","place":["Chile"]},{"name":"Centro Traslacional de Endocrinolog\u00eda UC (CETREN-UC) , Santiago ,","place":["Chile"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Delgado","sequence":"additional","affiliation":[{"name":"Endocrinolog\u00eda, Complejo Asistencial Dr S\u00f3tero del R\u00edo , Santiago ,","place":["Chile"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0668-412X","authenticated-orcid":false,"given":"Cristian A","family":"Carvajal","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago ,","place":["Chile"]},{"name":"Centro Traslacional de Endocrinolog\u00eda UC (CETREN-UC) , Santiago ,","place":["Chile"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5500-4434","authenticated-orcid":false,"given":"Carlos E","family":"Fardella","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, School of Medicine, Pontificia Universidad Cat\u00f3lica de Chile , Santiago ,","place":["Chile"]},{"name":"Centro Traslacional de Endocrinolog\u00eda UC (CETREN-UC) , Santiago ,","place":["Chile"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"2025052712250885200_CIT0001","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","article-title":"Primary aldosteronism and hypertensive disease","volume":"42","author":"Mosso","year":"2003","journal-title":"Hypertension"},{"key":"2025052712250885200_CIT0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0000000000002216","article-title":"Renal damage in primary aldosteronism: a systematic review and meta-analysis","volume":"38","author":"Monticone","year":"2020","journal-title":"J Hypertens"},{"key":"2025052712250885200_CIT0003","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1210\/jc.2016-1472","article-title":"Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis","volume":"101","author":"Kayser","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025052712250885200_CIT0004","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","article-title":"Primary aldosteronism: renaissance of a syndrome","volume":"66","author":"Young","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025052712250885200_CIT0005","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025052712250885200_CIT0006","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10495-006-4919-3","article-title":"Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression","volume":"11","author":"Mikkelsen","year":"2006","journal-title":"Apoptosis"},{"key":"2025052712250885200_CIT0007","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s10495-006-0286-3","article-title":"Spironolactone induces apoptosis and inhibits NF-kappaB independent of the mineralocorticoid receptor","volume":"11","author":"Sonder","year":"2006","journal-title":"Apoptosis"},{"key":"2025052712250885200_CIT0008","first-page":"1863","article-title":"Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology","volume":"85","author":"Fardella","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2025052712250885200_CIT0009","doi-asserted-by":"crossref","first-page":"905","DOI":"10.4067\/S0034-98872008000700014","article-title":"Primary aldosteronism","volume":"136","author":"Fardella","year":"2008","journal-title":"Rev Med Chil"},{"key":"2025052712250885200_CIT0010","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"key":"2025052712250885200_CIT0011","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of","volume":"71","author":"Whelton","year":"2017","journal-title":"Hypertension"},{"key":"2025052712250885200_CIT0012","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/ajh\/hpw056","article-title":"Usefulness and pitfalls in sodium intake estimation: comparison of dietary assessment and urinary excretion in Chilean children and adults","volume":"29","author":"Campino","year":"2016","journal-title":"Am J Hypertens"},{"key":"2025052712250885200_CIT0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-8587(24)00308-5","article-title":"Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort","volume":"13","author":"Yang","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025052712250885200_CIT0014","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/HJH.0000000000002843","article-title":"2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement","volume":"39","author":"Stergiou","year":"2021","journal-title":"J Hypertens"},{"volume-title":"Collaborating Centre for Drug Statistics Methodology. Daily defined dose: definition and general considerations","year":"2018","author":"WHO","key":"2025052712250885200_CIT0015"},{"key":"2025052712250885200_CIT0016","doi-asserted-by":"crossref","first-page":"14703203211003781","DOI":"10.1177\/14703203211003781","article-title":"Cardiovascular events and all-cause mortality in surgically or medically treated primary aldosteronism: a meta-analysis","volume":"22","author":"Jing","year":"2021","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2025052712250885200_CIT0017","doi-asserted-by":"crossref","first-page":"e220249","DOI":"10.1530\/JOE-22-0249","article-title":"Mineralocorticoid receptor signalling in primary aldosteronism","volume":"259","author":"Yang","year":"2023","journal-title":"J Endocrinol"},{"key":"2025052712250885200_CIT0018","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1530\/EJE-22-0375","article-title":"Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis","volume":"187","author":"Chen","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2025052712250885200_CIT0019","doi-asserted-by":"crossref","first-page":"e023813","DOI":"10.1161\/JAHA.121.023813","article-title":"Comparison of echocardiographic changes between surgery and medication treatment in patients with primary aldosteronism","volume":"11","author":"Ueda","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025052712250885200_CIT0020","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/HJH.0000000000000464","article-title":"Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness","volume":"33","author":"Holaj","year":"2015","journal-title":"J Hypertens"},{"key":"2025052712250885200_CIT0021","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/HYPERTENSIONAHA.119.13131","article-title":"Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function","volume":"74","author":"Kobayashi","year":"2019","journal-title":"Hypertension"},{"key":"2025052712250885200_CIT0022","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.2169\/internalmedicine.0438-17","article-title":"Effect of eplerenone on the glomerular filtration rate (GFR) in primary aldosteronism: sequential changes in the GFR during preoperative eplerenone treatment to subsequent adrenalectomy","volume":"57","author":"Nakano","year":"2018","journal-title":"Intern Med"},{"key":"2025052712250885200_CIT0023","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1210\/jc.2013-2180","article-title":"Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases","volume":"99","author":"Iwakura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2025052712250885200_CIT0024","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"key":"2025052712250885200_CIT0025","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1161\/HYPERTENSIONAHA.120.16909","article-title":"Time-dependent risk of atrial fibrillation in patients with primary aldosteronism after medical or surgical treatment initiation","volume":"77","author":"Kim","year":"2021","journal-title":"Hypertension"},{"key":"2025052712250885200_CIT0026","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1161\/HYPERTENSIONAHA.107.096925","article-title":"Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate","volume":"50","author":"Armanini","year":"2007","journal-title":"Hypertension"},{"key":"2025052712250885200_CIT0027","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/BF03345379","article-title":"Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate","volume":"28","author":"Armanini","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"2025052712250885200_CIT0028","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2265.2011.04243.x","article-title":"Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn\u2019s Registry","volume":"76","author":"Fischer","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025052712250885200_CIT0029","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2011-2563","article-title":"Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy","volume":"97","author":"Yoneda","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2025052712250885200_CIT0030","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-12-0912","article-title":"Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion","volume":"168","author":"Lucatello","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2025052712250885200_CIT0031","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0028-1087188","article-title":"Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis","volume":"41","author":"Ye","year":"2009","journal-title":"Horm Metab Res"},{"key":"2025052712250885200_CIT0032","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1210\/endo-99-4-1097","article-title":"Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria","volume":"99","author":"Cheng","year":"1976","journal-title":"Endocrinology"},{"key":"2025052712250885200_CIT0033","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1210\/jcem-44-6-1190","article-title":"Increased plasma 11-deoxycorticosterone during spironolactone medication","volume":"44","author":"Abshagen","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"2025052712250885200_CIT0034","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1289\/ehp.8138119","article-title":"Chemical suppression of steroidogenesis","volume":"38","author":"Colby","year":"1981","journal-title":"Environ Health Perspect"},{"key":"2025052712250885200_CIT0035","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1210\/endo-103-4-1313","article-title":"Relation of canrenone to the actions of spironolactone on adrenal cytochrome P-450 dependent enzymes","volume":"103","author":"Greiner","year":"1978","journal-title":"Endocrinology"},{"key":"2025052712250885200_CIT0036","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/S0021-9258(17)37833-X","article-title":"Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. Requirement for the 7alpha-thio group and evidence for the loss of the heme and apoproteins of cytochrome P-450","volume":"254","author":"Menard","year":"1979","journal-title":"J Biol Chem"},{"key":"2025052712250885200_CIT0037","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000138969","article-title":"Dose-dependent actions of spironolactone on the inner and outer zones of the guinea pig adrenal cortex","volume":"45","author":"Kossor","year":"1992","journal-title":"Pharmacology"},{"key":"2025052712250885200_CIT0038","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0303-7207(91)90211-A","article-title":"Mechanism of action of spironolactone on cortisol production by guinea pig adrenocortical cells","volume":"81","author":"Rourke","year":"1991","journal-title":"Mol Cell Endocrinol"},{"key":"2025052712250885200_CIT0039","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0026-895X(25)12955-6","article-title":"Role of the steroid 17 alpha-hydroxylase in spironolactone-mediated destruction of adrenal cytochrome P-450","volume":"40","author":"Kossor","year":"1991","journal-title":"Mol Pharmacol"},{"key":"2025052712250885200_CIT0040","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1038\/s41388-018-0654-9","article-title":"Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response","volume":"38","author":"Gold","year":"2019","journal-title":"Oncogene"},{"key":"2025052712250885200_CIT0041","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1084\/jem.20122292","article-title":"Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRgamma activation","volume":"210","author":"Leung","year":"2013","journal-title":"J Exp Med"},{"key":"2025052712250885200_CIT0042","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2249.2003.02249.x","article-title":"Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis","volume":"134","author":"Bendtzen","year":"2003","journal-title":"Clin Exp Immunol"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaf020\/61936173\/hpaf020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/38\/6\/354\/61936173\/hpaf020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/38\/6\/354\/61936173\/hpaf020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:25:21Z","timestamp":1748363121000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/38\/6\/354\/8019967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,2,18]]},"published-print":{"date-parts":[[2025,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaf020","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"type":"print","value":"0895-7061"},{"type":"electronic","value":"1941-7225"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,2,18]]}}}